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Abstract
Background: Leukoencephalopathy with Vanishing White Matter (VWM) is an autosomal recessive disorder caused
by germline mutations in the genes EIF2B1-5, which encode the 5 subunits of the eukaryotic translation initiation
factor eIF2B. To date, analysis of the biochemical effects of mutations in the EIF2B2-5 genes has been carried out,
but no study has been performed on mutations in the EIF2B1 gene. This gene encodes eIF2Bα, the smallest subunit
in eIF2B which has an important role in both the structure and regulation of the eIF2B complex.
Methods: eIF2B subunits were overexpressed in HEK293 cells and isolated from the resulting cell lysates by affinity
chromatography. Formation of the eIF2B complex and binding of its substrate, eIF2, was assessed by western blot.
Assays of the guanine nucleotide exchange (GEF) activity were also carried out.
Results: Of the 5 eIF2Bα mutations studied, we found 3 that showed loss or reduction of binding of eIF2Bα to the
rest of the complex, one with increased GEF activity, and one where no effects on activity or complex formation
were observed.
Conclusions: This is the first study on eIF2Bα VWM mutations. We show that some mutations cause expected
decreases in GEF activity or complex formation, similar to a majority of observed VWM mutations. However, we also
observe some unexpected changes which hint at other effects of these mutations on as yet undescribed functions
of eIF2B.
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Background
Leukoencephalopathy with vanishing white matter
(VWM; also known as childhood ataxia with central ner-
vous system hypomyelination (CACH)) is an autosomal
recessive neurological disorder with variable features
including progressive cerebellar ataxia, spasticity and cog-
nitive impairment [1]. VWM is characterised by chronic
degradation of central nervous system white matter due to
demyelination punctuated by episodes of rapid deterior-
ation following insults including head trauma, infection
with fever and acute fright [1].
Patients with VWM exhibit a broad range of disease
severities, from mild adult-onset VWM, where patients
exhibit less severe symptoms and survive many years
post diagnosis, to the most severe congenital form of the
disease, where patients are born with the disease and, at
best, survive only a few months [2, 3]. The disease mani-
fests in patients’ glial cells, particularly the astrocytes
and oligodendrocytes, the latter being responsible for
myelination in the central nervous system [4]. Studies in
a mouse model of VWM have shown both immature
myelination of white matter neurons, and a defect in
the inflammatory response, mediated by astrocytes, in
response to lipopolysacharride [5, 6].
VWM is caused by mutations in the EIF2B1-5 genes
encoding the subunits of the eukaryotic translation
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initiation factor eIF2B [3, 7]. eIF2B is a heterodecameric
complex comprising 5 subunits, termed α through ε in
order of increasing size, that acts as the guanine nucleo-
tide exchange factor (GEF) for the G-protein eIF2 [8].
GTP-bound eIF2 is responsible for loading the initiator
methionyl-tRNA onto the ribosome to allow initiation of
protein synthesis to take place [9]. Hence, eIF2B is a key
factor controlling the rate of protein synthesis in
cells. eIF2Bε contains the catalytic domain towards its
C-terminus [10]. The eIF2B subunits can be categorised
based on sequence homology and complex formation in
yeast [11]. eIF2Bγ and eIF2Bε form the catalytic subcom-
plex [12, 13]. eIF2Bα, β and δ form the regulatory sub-
complex, since this complex confers regulation by
increased phosphorylation of eIF2 which occurs in re-
sponse to cellular stresses [14]. In particular, eIF2Bα has
been shown to be required to mediate inhibition of eIF2B
by phospho-eIF2 [15, 16]. In mammalian cells, three eIF2B
complexes can be formed: eIF2Bα-ε form a decameric
complex (actually eIF2B(αβγδε)2 with 100 % relative activ-
ity; eIF2B(βγδε) is a tetrameric complex with 50 % relative
activity; and eIF2B(γε) is a dimeric complex with 20 %
activity [2, 8]. The eIF2B holocomplex comprises two
eIF2B(βγδε) heterotetramers held together by an eIF2Bα
dimer, although eIF2Bα dimerisation is not required to
link the heterotetramers [8].
One of the key regulatory mechanisms of eIF2B is
mediated by phosphorylation of the α subunit of its sub-
strate, eIF2, at Ser51 in response to cellular stresses in-
cluding viral infection, amino acid deprivation and
accumulation of unfolded proteins in the endoplasmic
reticulum [17]. Phosphorylated eIF2 binds more strongly
to, and inhibits, eIF2B, thereby preventing the recycling
of non-phosphorylated eIF2. GDP [16]. This leads to in-
hibition of general mRNA translation, although some
mRNAs are actually translated more efficiently, due to
the presence of specific features in their 5′-untranslated
regions, for example, the transcription factor ATF4 [18].
It has previously been shown that inappropriate activa-
tion of this pathway through inhibition of eIF2B by
VWM-associated mutations leads to accumulation of
ATF4 and its transcriptional targets [19–21].
To date, >150 individual VWM-associated mutations
have been identified, some being present homozygously
in particular patients, while others are compound het-
erozygous [3]. The majority of VWM mutations occur
in the EIF2B5 gene, which encodes the eIF2Bε subunit.
A limited genotype-phenotype relationship has been
established whereby the severity of the disease corre-
lates with particular mutations [3]. For example, muta-
tions in the EIF2B4 gene, encoding eIF2Bδ, appear to
result in more severe disease [2, 3]. The functional basis
for this is, however, unknown. We and others have pre-
viously shown that some of these mutations result in
changes in GEF activity and/or formation of the eIF2B
complex [2, 22, 23].
The relationship of these changes to disease severity
remains controversial. It has been suggested that defects
in GEF activity are predictive of disease severity [24].
However, we have shown that disease severity seems
unrelated to GEF activity defects, finding in some cases
that mutations resulting in very severe disease have little
or no defect in either complex formation or GEF activity
[2]. This suggests that there are perhaps other functions
of eIF2B that may also be affected. Indeed, Jennings et
al. recently showed that eIF2B is required to dissociate
eIF2. GDP from eIF5 (which possesses a GDP-
dissociation inhibitor (GDI) activity [25]) in order to
allow eIF2B to carry out GEF activity, thus giving it a
function as a GDI-dissociation factor (GDF) [26]. Their
studies in yeast established that this activity only re-
quires eIF2Bγ and ε and showed that eIF2B complexes
deficient in this GDF activity are able to slow translation
in a similar manner to some VWM mutations [26]. Since
GEF activity assays utilise purified eIF2, this activity is
unlikely to have been measured in previous studies.
To date, six VWM-associated mutations have been
identified in the EIF2B1 gene in patients (Table 1),
including four missense mutations, one in-frame dele-
tion and one nonsense mutation. While mutations in
other subunits have been examined, no comprehensive
study of mutations affecting eIF2Bα has been carried
out. Unfortunately, information regarding disease sever-
ity of patients with these mutations is limited. The only
patient with a described phenotype is one homozygous for
Val183Phe, who exhibited the milder late juvenile/early
adulthood disease [27]. eIF2Bα is unique among the eIF2B


































aNumbering starts with A of ATG start codon corresponding to nucleotide 82
of Genbank ID BC103763.1; G>A mutation of guanosine to
adenosine; del = deletion
bNumbering starts with first methionine of Genbank ID AAI03764;
Val183Phe =mutation of threonine 183 to phenylalanine; Gly204Δ = deletion
of glycine 204; ins = insertion; aa = amino acid
cMutation of first nucleotide of intron 2; IVS = intervening sequence
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subunits in that, in yeast, it is the only subunit whose dele-
tion can be tolerated [28]. Furthermore, it has been shown
to have ‘moonlighting’ roles outside of the eIF2B complex,
through interaction with the β-adrenergic receptor at the
cell membrane [29]. We have previously shown that the
Val183Phe variant disrupts formation of eIF2Bα homodi-
mers, but does not affect formation of eIF2B decamers [8].
Furthermore, Richardson et al. [30] reported decreased
stability of the Asn208Tyr variant in yeast cells. Here, we
have examined the biochemical effects of VWM muta-
tions in the EIF2B1 gene, encoding the eIF2Bα subunit.
We have studied both the ability of the mutated subunit
to incorporate into eIF2B complexes, including binding of
eIF2 and phospho-eIF2, and the effect of these mutations
on GEF activity.
Methods
Plasmids and site-directed mutagenesis
Plasmids containing myc-tagged eIF2B subunits and
His6-myc-tagged wild-type (WT) and Val183Phe eIF2Bα
have been described previously [2, 8, 22]. Site-directed
mutagenesis was carried out using Pfu DNA polymerase
(Promega, Southampton, UK) using primers shown in
Table 2. The mutations were confirmed by Sanger
sequencing of the entire insert.
Cell culture, transfection and lysis
HEK293 cells were obtained from ECACC (Salisbury, UK)
and maintained in Dulbecco’s modified eagles medium con-
taining 10 % fetal bovine serum and penicillin/streptomycin
(Life Technologies, Paisley, UK). Cells were transfected by
the calcium phosphate method as described previously [2].
The amount of vector used for each subunit was adjusted
to allow equal expression as assessed by western blotting
for the myc-tag.
48 h after transfection, lysates of transfected cells were
prepared by washing cells twice in cold phosphate-buffered
saline (PBS) followed by lysis in 20 mM Hepes-KOH
pH 7.6 containing 10 % (v/v) glycerol, 50 mM KCl,
0.5 % Triton X-100, 50 mM β-glycerolphosphate, 14.3 mM
β-mercaptoethanol, 0.5 mM EDTA and complete protease
inhibitors (Roche). Cell lysates were clarified by centrifu-
gation at 16,000× g for 15 min at 4 °C, aliquoted and stored
at −80 °C prior to use. A portion of each sample was
analysed by western blotting to determine the levels of
expression of transfected subunits.
Analysis of eIF2B complexes
Formation of recombinant eIF2B complexes was carried
out as previously described [2, 22]. Briefly, ~200 μg of lys-
ate was applied to 15 μl of Ni2+-NTA agarose (Qiagen,
Manchester, UK) and topped up to a final volume of
0.5 ml with lysis buffer containing a final concentration of
20 mM imidazole. After mixing for 1 h at 4 °C, the resin
was washed 3 times with cold lysis buffer containing
20 mM imidazole and eluted in 30 μl of SDS-PAGE
sample buffer containing 250 mM imidazole.
Bound material was analysed by western blot, reprobing
the same membrane for myc-tag, total and phospho-eIF2α.
Antibodies to phosphorylated (#3597) and total (#2103)
eIF2α were purchased from Cell Signalling Technology
(Hitchin, Hertfordshire, UK). Anti-myc tag antibody
(60003-2-lg) was purchased from Proteintech (Manchester,
UK). Anti-β-actin antibody (A4700) was purchased from
Sigma Aldrich (Poole, Dorset, UK).
Measurement of eIF2B nucleotide exchange activity
Measurements of eIF2B GEF activity were carried out as
previously described [2, 22]. For analysis of the effects of
eIF2 phosphorylation on activity, we phosphorylated puri-
fied eIF2 in vitro. Briefly, eIF2 was incubated with recom-
binant PKR (Life Technologies, Paisley, UK) for 30 min at
30 °C in kinase buffer (20 mM Tris–HCl pH 7.5, 10 mM
MgCl2, 1 mM EGTA, 1 mM Na3VO4, 5 mM NaF, 2 mM
DTT, 0.02 % Triton X-100) containing 200 μM ATP prior
to labelling with 3H-GDP. Control eIF2 was treated in the
same conditions, but excluding PKR and ATP from the
buffer.
Data are expressed as mean+/− SEM with the activity of
WT complexes being set as 100 %. Statistical analysis was
carried out in Graphpad Prism and p-values were generated
using an unpaired t-test with Welch’s correction.
Structural rendering
Molecular graphics and analyses were performed with
the UCSF Chimera package (v1.9) using the pdf file
3ECS [31, 32]. Chimera is developed by the Resource for
Biocomputing, Visualization, and Informatics at the
Table 2 Primer sequences used to generate mutant plasmids
Mutation Mutagenesis primer sequences
Val183Phe F – 5′ GTG CTA GAT GCT GCT TTC GGC TAC ATC ATG G 3′
R – 5′ CCA TGA TGT AGC CGA AAG CAG CAT CTA GCA C 3′
Gly204Δ F – 5′GAA GGA GTT GTT GAA AAC GGA ATT ATT AAC AAG
ATT GGA AC 3′
R – 5′ GTT CCA ATC TTG TTA ATA ATT CCG TTT TCA ACA
ACT CCT TC
Asn208Tyr F – 5′ GAA AAC GGA GGA ATT ATT TAC AAG ATT GGA ACC
AAC C 3′
R – 5′ GGT TGG TTC CAA TCT TGT AAA TAA TTC CTC CGT
TTT C 3′
Tyr275Cys F – 5′ CGT GGG TCG ACT GCA CTG CCC CTT C 3′
R – 5′ GAA GGG GCA GTG CAG TCG ACC CAC G 3′
Pro278Arg F – 5′ CGA CTA CAC TGC CCG TTC CTT AAT CAC TC 3′
R – 5′ GAG TGA TTA AGG AAC GGG CAG TGT AGT CG 3′
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University of California, San Francisco (supported by
NIGMS P41-GM103311).
Results and discussion
Structural mapping of eIF2B subunits
The atomic resolution structure of eIF2Bα has been
previously solved by Hiyama et al. [31]. We have re-
cently demonstrated that this subunit forms a homodi-
mer (Fig. 1a) [8]. All the missense or in-frame deletion
mutations map to the Rossman-fold domain, comprising
two antiparallel β-sheets surrounded by several α-helices
(Fig. 1a). The Val183Phe variant maps to the dimeric
interface and we have previously shown that this mutation
is able to disrupt formation of eIF2Bα homodimers. How-
ever, this disruption did not affect formation of eIF2B dec-
amers, thus its effect on eIF2B activity remains unknown
[8]. The remaining four sites of mutations, Gly204,
Asn208, Tyr275 and Pro278 all occur on two adjacent β-
strands in the subunit. Indeed, in the structure, Gly204
and Pro278 are adjacent in space, although they do not
appear to interact (Fig. 1a).
Hiyama et al. [31] identified a pocket containing a
sulphate ion in the structure of eIF2Bα and proposed that,
since eIF2Bα is required for the inhibitory binding of
phosphorylated eIF2 to the eIF2B complex, this pocket
may be the binding site of the phosphorylated serine resi-
due. Interestingly, the side chain of Asn208 protrudes into
this site and co-ordinates a water molecule that interacts
with the sulphate ion (Fig. 1b). Mutation of this residue to
tyrosine may cause a large steric change which may affect
binding of phospho-eIF2 into this pocket (Fig. 1b).
Effects of eIF2Bα VWM mutants on subunit stability and
complex formation
We over-expressed myc-tagged eIF2B subunits, includ-
ing hexahistidine (His6)-myc-tagged eIF2Bα in HEK293
cells. Since the Asn208Tyr mutation has been previously
described as destabilising eIF2Bα when overexpressed in
yeast cells [30], we analysed expression of each of the
mutant subunits by western blotting (Fig. 2a). We did
not find consistent destabilisation caused by any of the
mutations, including Asn208Tyr, in contrast to the data
of Richardson et al. based on studies performed in
Saccharomyces cerevisiae [30]. This apparent discrepancy
is likely due to differences between yeast and mammals.
In order to examine the effects of the mutations on
the integrity of eIF2B complexes, overexpressed eIF2B
complexes were isolated on Ni2+-NTA agarose and ana-
lysed by western blot for myc-tag, in order to assess
complex formation, eIF2α and phospho-S51-eIF2α, in
order to assess substrate binding (Fig. 2b). Quantification
of multiple experiments showed that three mutations,
Val183Phe, Gly204Δ and Tyr275Cys, affected complex
formation (Fig. 2b). The Gly204Δ mutant is unable to
interact with any of the other subunits of the eIF2B com-
plex, whereas Tyr275Cys and Val183Phe lead to an ap-
proximately 50 % reduction in binding of this subunit to
the rest of the complex (Fig. 2b). The other mutations did
not affect binding to the other subunits.
A precedent has been set for reduced or loss of eIF2Bα
binding to the rest of the eIF2B complex as a means of
VWM mutations exhibiting a pathological effect; we have
previously shown that the Gly329Val mutation of eIF2Bβ
leads to loss of the interaction of eIF2Bα. This is associ-
ated with a 50 % reduction of activity of the complexes,
identical to the activity of eIF2B complexes entirely
lacking eIF2Bα [2]. Thus, loss or reduced binding of
eIF2Bα caused by the Gly204Δ and Tyr275Cys mutations,
which were reported together in the same patient [33], is
likely to result in the disease.
Reprobing the blots for total and phospho-eIF2α re-
vealed no reduction in binding of the substrate to the
complexes caused by the different mutants, save where
complex formation was affected (Fig. 2b). Quantification
of total and phospho-eIF2 binding showed decreased
binding of eIF2 to the mutants resulting in decreased
complex formation, but no difference in the ratio of eIF2
to phospho-eIF2 was observed (Fig. 2d). This was sur-
prising for Asn208Tyr, given the location of the muta-
tion relative to the predicted phosphate-binding pocket,
which would be expected to result in reduced binding to
phospho-eIF2 (Fig. 1b). However, it is possible that this
pocket is not actually responsible for strengthening the
interaction of eIF2B with phosphorylated eIF2α, since
the interaction was modelled in silico and no experi-
ments have been carried out to confirm this [31].
Effects of VWM mutations on eIF2B GEF activity
In order to measure the effects of the mutations on
eIF2B activity, we carried out GEF activity assays on
eIF2B complexes containing WT and mutant eIF2Bα
subunits. Since the Val183Phe, Gly204Δ and Tyr275Cys
mutations show reduced interaction with the rest of the
complex, we would assume that the levels of catalytic
ε-subunit would be reduced and any effects on intrinsic
activity would thus be hard to interpret, Since eIF2Bβγδε
tetrameric complexes can form in the absence of eIF2Bα,
reduction or abolition of interaction with other subunits
would not lead to total abolition of eIF2B activity, but
would instead result in a prevalence of the less active
eIF2B(βγδε) tetramers [2, 8]. We have therefore assumed
that cells containing these mutations would show reduced
eIF2B GEF activity due to a reduction in levels of the most
active decameric eIF2B complex. However, we did carry
out activity assays on the Val183Phe mutant in order to
confirm this reduced activity.
The activity data (Fig. 3a) from multiple experiments
show a decrease in GEF activity only for the Val183Phe
Wortham and Proud BMC Medical Genetics  (2015) 16:64 Page 4 of 8
Fig. 1 Location of mutations of eIF2Bα on its structure. a Structure of the eIF2Bα dimer showing the location of the mutated residues. All the
VWM associated mutations affect sites in the α-helix and β-sheet rich Rossmann-like fold rather than the α-helical bundle furthest from the
interaction interface of the homodimer. b The effect of the Asn208Tyr mutation on the proposed phospho-eIF2 binding pocket. The ribbon
and spacefill structures show the location of the pocket on the structure of a single monomer of the subunit. The right hand panels show the
WT (Asn208) residue relative to the sulphate ion mimicking a phosphate group and a co-ordinating water molecule (upper panel), and the
predicted change to the pocket following in silico mutation of Asn208 to Tyr
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mutation, which showed an approximately 30 % decrease
in activity, as would be expected for the decreased inter-
action. Intriguingly, the Asn208Tyr mutation causes a sig-
nificant 40 % increase in GEF activity compared to wild-
type complexes. The Pro278Arg mutation has no effect
on GEF activity.
The increased GEF activity caused by the Asn208Tyr
mutation is not a unique observation among VWM mu-
tations (for example, Val73Gly of eIF2Bε [2]). As de-
scribed above, the Asn208Tyr mutation was predicted to
affect the phosphate binding pocket described in [31].
However, we saw no effect on binding (Fig. 2b). A num-
ber of mutations have been described that overcome the
inhibitory effects of eIF2α phosphorylation in yeast, in
particular the Glu199Lys (Glu198Lys in human eIF2Bα),
which also occurs in this predicted pocket [28]. There-
fore, it is possible that Asn208Tyr alleviates inhibition
by phospho-eIF2, but without affecting its binding, lead-
ing to the increase in eIF2B activity. It is unknown how
this relates to the disease phenotype. In order to test
study this, we carried out in vitro GEF assays using eIF2
which is some cases had been pretreated with the eIF2
kinase PKR to phosphorylate it (Fig. 3b). We observed
that, as expected, phosphorylation of eIF2 reduced the
activity of eIF2B containing either WT or Asn208Tyr
eIF2Bα (Fig. 3c). Although complexes containing the
Asn208Tyr mutant did tend to show higher activity
against phosphorylated eIF2 compared to the wild-type
eIF2B (Fig. 3c), this difference was not statistically sig-
nificant (p = 0.2535) (Fig. 3d). Therefore, there is no sig-
nificant difference in the ability of phospho-eIF2 to
inhibit eIF2B containing WT eIF2Bα or the Asn208Tyr
mutant.
The lack of an effect of the Pro278Arg mutation on
GEF activity is, again, not surprising since a number of
mutations, even including some that cause severe dis-
ease (such as Ala391Asp in eIF2Bδ) show no effect on
either GEF activity or complex formation [2]. It is pos-
sible that disruption of, as yet, undescribed functions of
Fig. 2 Biochemical effects of mutations of eIF2Bα on eIF2B complex
formation. a HEK293 cells were transfected with plasmids encoding
myc-tagged eIF2B subunits andHis6-myc-tagged eIF2Bα. ‘No His-tag’
indicates that a vector encoding myc-tagged eIF2Bα was used instead.
Lysates from transfected cells were analysed by western blotting for
the myc tag to verify even expression of each subunit. An actin loading
control is included. b Lysates were subjected to affinity purification
using Ni2+ agarose and the bound material was analysed by western
blot for myc tag to test for the presence of other subunits associated
with His6-mys-eIF2Bα and phospho- and total eIF2α to assess substrate
binding. c The myc-signal for the WT and indicated mutations were
quantified and normalised to the level of eIF2Bα. Data are shown
relative to the level of the WT pulldown. Data are shown as the relative
expression to WT ± SEM of 3 independent experiments. P-values are as
indicated on the figure. d Levels of total and phospho-eIF2 from
pulldowns were quantified and normalised to the level of eIF2Bα
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eIF2B may underlie the pathological effect of this
mutation.
Conclusions
This study is the first focused study on VWM-associated
mutations in the EIF2B1 gene encoding eIF2Bα. Previous
studies have shown effects of VWM mutations on both
eIF2B complex formation and GEF activity [2, 22, 23],
both of which are observed in this cohort of mutations.
However, we also observe that two mutations lead either
to increased GEF activity or no change, without affecting
complex formation. Along with previous studies, this
suggests that these mutations may affect other, as yet
undetermined functions of the eIF2B complex. The re-
cently observed GDF activity of the complex sets a pre-
cedent for the identification of these alternative
functions [26]. Previous studies have also suggested a
genotype-phenotype relationship between particular
VWM mutations and disease severity [3]. However, a
lack of reports on the phenotype for the majority of
VWM mutations in EIF2B1 makes it impossible to iden-
tify any such relationships for these mutations. The data
in this study add to the increasing body of evidence
demonstrating a wide variety of effects of mutations of
the eIF2B complex in VWM patients, and shows that we
are still some distance from understanding the molecu-
lar basis of this disease.
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Fig. 3 Effects of eIF2Bα mutations on GEF activity and inhibition by
phosphorylated eIF2. a eIF2B GEF activity assays were carried out on
complexes containing the mutant eIF2Bα subunits that do not affect
eIF2B complex formation. Data are shown as the GEF activity relative
to WT, which is set to 100 %. Activities are shown as mean ± SEM of
six independent experiments. P-values were calculated by t-test with
Welch’s correction. b Western blot showing the increase in eIF2α
phosphorylation following treatment with PKR. c eIF2B GEF activity
assays were carried out on complexes containing WT or Asn208Tyr
eIF2Bα using either unphosphorylated or in vitro phosphorylated eIF2.
Data are shown as the GEF activity relative to WT, which is set to
100 %. Activities are shown as mean ± SEM of four independent
experiments. P-values were calculated by t-test with Welch’s correction.
d The data from (c) with the activity for assays with unphosphorylated
eIF2 set to 100 % in order to compare the relative decrease in activity
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